Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

Completed · Phase 1/Phase 2

Conditions studied: Stroke, Acute

In brief

The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.

Key facts

Study ID

NCT00630396

Run by

David Hess, MD

People needed

60

Starts

2008-05-01

Expected to finish

2010-01-01

Last updated by the study team

2012-01-13

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• over 18 years of age
• acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
• onset of symptoms less than 6 hours
• measurable neurologic deficit (National Institutes of Health [NIH] Stroke Scale >/= 1)

You may not qualify if…

• allergy to tetracycline antibiotics
• women of child-bearing potential
• known hepatic and/or renal insufficiency
• Thrombocytopenia
• history of intolerance to minocycline
• dizziness at the time of stroke or in the past month (by self-report)
• aphasia likely to interfere with patients ability to report adverse effects
• previous functional disability
• stuporous or comatose
• presence of another serious illness likely to confound the study
• unlikely to be available for 90 day follow-up
• severe stroke (National Institutes of Health [NIH] Stroke Scale >22)
• undergoing an interventional neuro-radiological intervention in first 12 hour

Where it is running

• University of Kentucky — Lexington, Kentucky, United States
• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.